---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-017853"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:43:00.195946+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q1 net loss widens to $76.7M; delays RGX-202 Duchenne trial initiation to H1 2023

## Summary
- Net loss of $76.7M ($1.79/sh) vs $50.1M loss ($1.20/sh) in Q1 2021; revenue $22.2M up 17% YoY on Zolgensma royalties.
- Cash $764.8M, operational runway into 2025; net loss includes $9.2M non-recurring charge from UPenn license amendment.
- RGX-314 pivotal trials for wet AMD on track; BLA submission expected in 2024.
- RGX-202 Duchenne trial dosing delayed to H1 2023 due to manufacturing observation; trial prep continues.
- cGMP manufacturing facility operational for up to 2000L scale; '5x'25' strategy to advance five AAV therapeutics by 2025.

## SEC filing metadata
- accession: 0001564590-22-017853
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000156459022017853/0001564590-22-017853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000156459022017853/rgnx-8k_20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-017853
- JSON: https://secwatch.observer/filing/0001564590-22-017853.json
- Plain text: https://secwatch.observer/filing/0001564590-22-017853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.